Stock SUMMIT CORPORATION PLC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Summit Corporation plc London S.E.

Equities

GB00B02T3K57

End-of-day quote London S.E.
Other stock markets
- GBX - Intraday chart for Summit Corporation plc
Apr. 11 Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors CI
Apr. 09 Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed RE

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
BU
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
BU
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
BU
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
AQ
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
BU
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
PR
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
PR
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
BU
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024
AQ
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
BU
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
AQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
AQ
Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
BU
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
BU
Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
BU
Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SMMT Stock
  4. Stock
  5. News Summit Corporation plc
  6. Press Releases